Robert Marcus
Stock Analyst at JP Morgan
(1.35)
# 3,574
Out of 5,050 analysts
22
Total ratings
47.06%
Success rate
-2.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEN Penumbra | Maintains: Neutral | $265 → $275 | $266.19 | +3.31% | 4 | Nov 6, 2025 | |
| IART Integra LifeSciences Holdings | Upgrades: Neutral | $75 | $12.04 | +522.92% | 2 | Dec 17, 2021 | |
| BDX Becton, Dickinson and Company | Downgrades: Neutral | $265 | $177.84 | +49.01% | 10 | Aug 6, 2021 | |
| GKOS Glaukos | Downgrades: Underweight | $50 | $83.86 | -40.38% | 2 | Oct 8, 2020 | |
| TMDX TransMedics Group | Downgrades: Neutral | $15 | $119.17 | -87.41% | 2 | Oct 8, 2020 | |
| ATRC AtriCure | Maintains: Overweight | $48 → $57 | $32.05 | +77.85% | 2 | Jul 29, 2020 |
Penumbra
Nov 6, 2025
Maintains: Neutral
Price Target: $265 → $275
Current: $266.19
Upside: +3.31%
Integra LifeSciences Holdings
Dec 17, 2021
Upgrades: Neutral
Price Target: $75
Current: $12.04
Upside: +522.92%
Becton, Dickinson and Company
Aug 6, 2021
Downgrades: Neutral
Price Target: $265
Current: $177.84
Upside: +49.01%
Glaukos
Oct 8, 2020
Downgrades: Underweight
Price Target: $50
Current: $83.86
Upside: -40.38%
TransMedics Group
Oct 8, 2020
Downgrades: Neutral
Price Target: $15
Current: $119.17
Upside: -87.41%
AtriCure
Jul 29, 2020
Maintains: Overweight
Price Target: $48 → $57
Current: $32.05
Upside: +77.85%